Atopic dermatitis (AD) is the most frequent allergic disease in dogs. AD can be treated using allergenspecific immunotherapy as well as symptomatic antipruritic treatment including the use of lokivetmab - caninized anti-interleukine-31 antibody.The aim of the study was to evaluate the effectiveness of lokivetmab over 12 weeks of treat-ment. Studies have been carried out in 89 dogs. In all affected animals, the severity of lesions was assessed using the CADESI 04 and the pruritus was assessed using the VAS.After the first dose of lokivetmab, both CADESI 04 and VAS statistical decreased by 4 weeks from 40.48 to 20.31, and from 7.42 to 2.48, respectively (p = 0.0000001) maintained significantly decresed values during the whole treatment period (CADESI 04 15.64, 15.07 after 8 and 12 weeks, respectively, PVAS 2.03, 1.95 after 8 and 12 weeks, respectively).Lokivetmab leads to a significant reduction of CADESI 04 and pruritus, within four weeks and maximum effect is achived after the second dose.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.24425/pjvs.2020.132765 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis.
Vet Dermatol
January 2025
Elanco Animal Health, Greenfield, Indiana, USA.
Background: Janus kinase inhibitors (JAKi) have been shown to reduce pruritus and improve associated inflammatory skin lesions in canine atopic dermatitis (cAD).
Objective: To evaluate the efficacy and safety of ilunocitinib, in comparison to oclacitinib, for the control of cAD in a randomised, blinded trial.
Animals: Three-hundred-and-thirty-eight dogs with cAD.
Immunotherapy using pullulan-conjugated Der f 2 allergen in canine atopic dermatitis: An anti-inflammatory agent-sparing approach.
Vet Dermatol
December 2024
Zenoaq, Koriyama, Fukushima, Japan.
Background: Allergen immunotherapy is used as aetiological treatment for canine atopic dermatitis (cAD).
Objective: To assess the anti-inflammatory agent-sparing effect over 1 year of immunotherapy using pullulan-conjugated recombinant Der f 2 (rDf2-P).
Animals: Twenty-one privately owned dogs with cAD.
A randomized double-blind clinical trial: Comparison of oclacitinib with a traditional Chinese herbal medicine product (Dihuang Guiqin capsule) in the treatment of canine atopic dermatitis.
Res Vet Sci
May 2024
Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Chinese Academy of Agricultural Sciences, Lanzhou 730050, PR China. Electronic address:
Canine atopic dermatitis (cAD) is a common chronic inflammatory skin disease, which seriously affects the quality of life for both dogs and their owners. Currently, the common therapeutic drugs in the clinic have disadvantages such as obvious adverse effects and high prices. Traditional Chinese herbal medicine (TCHM) has great potential for the treatment of cAD.
View Article and Find Full Text PDFA placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs.
Vet Dermatol
August 2024
Clinic for Small Animals, Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany.
Background: Supplementation of polyunsaturated fatty acids (PUFA) enables dose reduction of prednisolone and ciclosporin in canine atopic dermatitis (cAD).
Objective: To determine if oral administration of PUFA reduces the dose of oclacitinib in cAD.
Animals: Twenty-two client-owned dogs with cAD receiving oclacitinib.
Establishment of clinical criteria for the diagnosis of adverse food reactions in dogs with atopic dermatitis.
Vet Dermatol
August 2024
Clinic of Medicine, Faculty of Veterinary Science, University of Thessaly, Karditsa, Greece.
Background: Diagnosis of canine adverse food reactions (AFRs) is based on vague criteria, such as '>50% improvement' during elimination diet trial (EDT) followed by 'deterioration' during provocation test (PT).
Objective: The objective of the study was to use predefined criteria to evaluate response during EDT [i.e.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!